266 related articles for article (PubMed ID: 30728464)
1. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.
Ideno N; Yamaguchi H; Okumura T; Huang J; Brun MJ; Ho ML; Suh J; Gupta S; Maitra A; Ghosh B
Lab Invest; 2019 Jul; 99(8):1233-1244. PubMed ID: 30728464
[TBL] [Abstract][Full Text] [Related]
2. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing.
Chiou SH; Winters IP; Wang J; Naranjo S; Dudgeon C; Tamburini FB; Brady JJ; Yang D; Grüner BM; Chuang CH; Caswell DR; Zeng H; Chu P; Kim GE; Carpizo DR; Kim SK; Winslow MM
Genes Dev; 2015 Jul; 29(14):1576-85. PubMed ID: 26178787
[TBL] [Abstract][Full Text] [Related]
5. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
Bloomer H; Smith RH; Hakami W; Larochelle A
Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
[TBL] [Abstract][Full Text] [Related]
6. Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.
Li F; Hung SSC; Mohd Khalid MKN; Wang JH; Chrysostomou V; Wong VHY; Singh V; Wing K; Tu L; Bender JA; Pébay A; King AE; Cook AL; Wong RCB; Bui BV; Hewitt AW; Liu GS
Hum Gene Ther; 2019 Nov; 30(11):1349-1360. PubMed ID: 31373227
[TBL] [Abstract][Full Text] [Related]
7. Precise and efficient silencing of mutant Kras
Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
[No Abstract] [Full Text] [Related]
8. Inducible Genome Editing with Conditional CRISPR/Cas9 Mice.
Katigbak A; Robert F; Paquet M; Pelletier J
G3 (Bethesda); 2018 May; 8(5):1627-1635. PubMed ID: 29519936
[TBL] [Abstract][Full Text] [Related]
9.
Chang YJ; Bae J; Zhao Y; Lee G; Han J; Lee YH; Koo OJ; Seo S; Choi YK; Yeom SC
J Vet Sci; 2020 Mar; 21(2):e26. PubMed ID: 32233134
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of single-stranded DNA donors to generate conditional null mouse alleles.
Lanza DG; Gaspero A; Lorenzo I; Liao L; Zheng P; Wang Y; Deng Y; Cheng C; Zhang C; Seavitt JR; DeMayo FJ; Xu J; Dickinson ME; Beaudet AL; Heaney JD
BMC Biol; 2018 Jun; 16(1):69. PubMed ID: 29925370
[TBL] [Abstract][Full Text] [Related]
11. Modeling Pancreatic Cancer through Somatic Editing with AAV.
Curiel-GarcÍa A; Olive KP
Trends Mol Med; 2019 May; 25(5):361-362. PubMed ID: 30878400
[TBL] [Abstract][Full Text] [Related]
12. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
13. Designing Genetically Engineered Mouse Models (GEMMs) Using CRISPR Mediated Genome Editing.
Desjardins J; Cowan M; Yamanaka Y
Methods Mol Biol; 2022; 2429():515-531. PubMed ID: 35507186
[TBL] [Abstract][Full Text] [Related]
14. P53 ICE CRIM mouse: a tool to generate mutant allelic series in somatic cells and germ lines for cancer studies.
Fan HH; Yu IS; Lin YH; Wang SY; Liaw YH; Chen PL; Yang TL; Lin SW; Chen YT
FASEB J; 2019 Apr; 33(4):5571-5584. PubMed ID: 30640520
[TBL] [Abstract][Full Text] [Related]
15. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
[TBL] [Abstract][Full Text] [Related]
16. Genome editing with the donor plasmid equipped with synthetic crRNA-target sequence.
Ishibashi R; Abe K; Ido N; Kitano S; Miyachi H; Toyoshima F
Sci Rep; 2020 Aug; 10(1):14120. PubMed ID: 32839482
[TBL] [Abstract][Full Text] [Related]
17. Somatic Gene Editing of
McCullough KT; Boye SL; Fajardo D; Calabro K; Peterson JJ; Strang CE; Chakraborty D; Gloskowski S; Haskett S; Samuelsson S; Jiang H; Witherspoon CD; Gamlin PD; Maeder ML; Boye SE
Hum Gene Ther; 2019 May; 30(5):571-589. PubMed ID: 30358434
[TBL] [Abstract][Full Text] [Related]
18. Gene editing vectors for studying nicotinic acetylcholine receptors in cholinergic transmission.
Peng C; Yan Y; Kim VJ; Engle SE; Berry JN; McIntosh JM; Neve RL; Drenan RM
Eur J Neurosci; 2019 Aug; 50(3):2224-2238. PubMed ID: 29779223
[TBL] [Abstract][Full Text] [Related]
19. Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing.
Fu YW; Dai XY; Wang WT; Yang ZX; Zhao JJ; Zhang JP; Wen W; Zhang F; Oberg KC; Zhang L; Cheng T; Zhang XB
Nucleic Acids Res; 2021 Jan; 49(2):969-985. PubMed ID: 33398341
[TBL] [Abstract][Full Text] [Related]
20. Genome editing using CRISPR/Cas9-based knock-in approaches in zebrafish.
Albadri S; Del Bene F; Revenu C
Methods; 2017 May; 121-122():77-85. PubMed ID: 28300641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
